Approximately 5%-10% of prostate cancers (notably those with neuroendocrine differentiation) display low PSMA expression (SUVmax < 10), and a missed diagnosis could potentially delay treatment (57, 58). The gene discussed is FOLH1; the disease is prostate carcinoma.